You are viewing the site in preview mode
Skip to main content
| |
LY (95% CI)
|
QALY (95% CI)
|
Cost, € (95% CI)
|
|---|
|
Deterministic analysis (undiscounted)
|
|
Cetuximab + BSC
|
0.61
|
0.48
|
37,146
|
|
BSC
|
0.32
|
0.24
|
3678
|
|
Incremental
|
0.29
|
0.25
|
33,468
|
|
ICER
|
115,690
|
134,495
| |
|
Deterministic analysis (discounted)
|
|
Cetuximab + BSC
|
0.61
|
0.48
|
36,637
|
|
BSC
|
0.32
|
0.23
|
3648
|
|
Incremental
|
0.29
|
0.25
|
32,989
|
|
ICER
|
114,907
|
133,527
| |
|
PSA (undiscounted)
|
|
Cetuximab + BSC
|
0.61 (0.57–0.64)
|
0.48 (0.45–0.51)
|
36,915 (26,773–48,716)
|
|
BSC
|
0.32 (0.30–0.34)
|
0.24 (0.22–0.25)
|
3639 (2520–4982)
|
|
Incremental
|
0.29 (0.25–0.33)
|
0.25 (0.21–0.28)
|
33,276 (22,720–45,027)
|
|
ICER
|
116,030 (80,417–158,009)
|
134,777 (92,521–184,072)
| |
|
PSA (discounted)
|
|
Cetuximab + BSC
|
0.61 (057–0.64)
|
0.48 (0.45–0.51)
|
36,410 (26,407–48,053)
|
|
BSC
|
0.32 (0.30–0.34)
|
0.24 (0.22–0.25)
|
3609 (2498–4942)
|
|
Incremental
|
0.29 (0.24–0.33)
|
0.25 (0.21–0.28)
|
32,801 (22,394–44,397)
|
|
ICER
|
115,248 (79,861–156,946)
|
133,812 (92,521–184,072)
| |
- BSC best supportive care, ICER incremental cost-effectiveness ratio, LY life-year, PSA probabilistic sensitivity analysis, QALY quality-adjusted life-year
